Shaghayegh Baradaran Ghavami | Molecular Biology | Best Researcher Award

Dr. Shaghayegh Baradaran Ghavami | Molecular Biology | Best Researcher Award

IBD research, Research institutes gastroenterology and liver, Iran 

Shaghayegh Baradaran Ghavami is a dedicated researcher with over 10 years of expertise in immunology, microbiology, and molecular biology. Specializing in autoimmune diseases like Inflammatory Bowel Disease (IBD), her work focuses on innovative therapies such as probiotics, nanocomposites, and viral infection impacts on immune responses in autoimmune patients. She is highly skilled in advanced molecular techniques, including RNA/DNA extraction, flow cytometry, microbiological assays, and animal model studies. With a strong background in mentoring Master’s and Ph.D. students, she has contributed significantly to multiple high-impact publications. Passionate about advancing knowledge in immune-mediated diseases, Shaghayegh’s work has led to groundbreaking approaches in diagnostics and therapeutic development.

Profile

Education

Shaghayegh Baradaran Ghavami holds a Ph.D. in Microbiology from Azad University, Science and Research Branch, Tehran, Iran (2010-2015). Prior to that, she completed her M.Sc. in Microbiology at Islamic Azad University, North Tehran Branch, Iran (2008-2010). Her extensive academic background laid the foundation for her research in immunology and microbiology, specifically focusing on autoimmune diseases. Throughout her education, Shaghayegh demonstrated a commitment to deepening scientific understanding, leading her to pursue a career in both laboratory and clinical research, where she has made significant contributions to advancing medical practices and patient outcomes.

Experience

Shaghayegh Baradaran Ghavami has over a decade of experience in both clinical and academic research. She is currently a Postdoctoral Fellow at the Research Institute for Gastroenterology and Liver Disease at Shaheed Beheshti University of Medical Sciences (2018-2026), where she oversees research design, data analysis, and project dissemination. Previously, she served as a Clinical Research Fellow at the same institution (2016-2018), where she coordinated research teams and contributed to numerous publications. Additionally, she worked as a tutor at Azad University, Tehran, supporting students through complex microbiological concepts and promoting critical thinking. Her professional experience spans across experimental research, research proposal development, grant management, and academic mentoring.

Awards and Honors

Shaghayegh Baradaran Ghavami has received several prestigious recognitions in her research career. In 2020, she was awarded a $30,000 research grant from Orchid Life Company for her project on IBD and COVID-19. Her work has also earned her opportunities to present at major international conferences, such as the “Advanced Immunology 2023” congress in London and the “Microbiota MI 2020” meeting in Milan. Her research achievements are consistently acknowledged through citations in high-impact journals, showcasing her contributions to the fields of immunology and microbiology. Shaghayegh’s awards and honors reflect her dedication to advancing scientific knowledge and therapeutic innovations in autoimmune diseases.

Research Focus

Shaghayegh Baradaran Ghavami’s research is focused on advancing the understanding of immune-mediated diseases, particularly Inflammatory Bowel Disease (IBD). Her work explores the immunomodulatory effects of probiotics, the role of the gut microbiota, and the use of nanocomposite-based therapies to manage autoimmune diseases. She investigates the mechanisms underlying the interaction between viral infections and immune responses in IBD patients, providing insights into new therapeutic approaches. Shaghayegh’s research aims to develop novel diagnostic tools and interventions that can improve the quality of life for individuals suffering from autoimmune conditions. Her studies have contributed to enhancing the understanding of dendritic cells, immunological markers, and their potential as therapeutic targets for IBD.

Publication Top Notes

  • “Alterations of the human gut Methanobrevibacter smithii as a biomarker for inflammatory bowel diseases” 📚🦠
  • “Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory…” 🔬🧬
  • “The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study” 🌏📊
  • “Mesenchymal stem cell spheroids embedded in an injectable thermosensitive hydrogel: an in situ drug formation platform for accelerated wound healing” 🧫💉
  • “Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease” 🦠🧘‍♀️
  • “Cross-talk between immune system and microbiota in COVID-19” 🦠🌍
  • “Overview of three proliferation pathways (Wnt, Notch, and Hippo) in intestine and immune system and their role in inflammatory bowel diseases (IBDs)” 🔬🧬
  • “Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy” 💊🦠
  • “Probiotic-induced tolerogenic dendritic cells: a novel therapy for inflammatory bowel disease?” 💉🔬
  • “Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice” 🤔💊
  • “The critical role of gut-brain axis microbiome in mental disorders” 🧠🌱

 

 

NARESH BABU CHILAMAKURU | Molecular Biology | Best Researcher Award

Dr NARESH BABU CHILAMAKURU | Molecular Biology | Best Researcher Award

Assistant Professor, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, India

Dr. C. Naresh Babu, M. Pharm., Ph.D., is an accomplished academician and researcher with expertise in medicinal chemistry, pharmaceutical sciences, and drug discovery. Currently an Assistant Professor at Raghavendra Institute of Pharmaceutical Education & Research (RIPER) in Ananthapuramu, India, Dr. Naresh Babu has contributed significantly to the field of pharmacy through research in drug development, molecular docking, and QSAR studies. His work focuses on synthesizing novel compounds for treating tuberculosis and other diseases. With over a decade of teaching experience, he is also recognized for his leadership in coordinating research and quality assurance at RIPER. He has published numerous research papers in esteemed journals and holds various professional memberships.

Profile

Google Scholar

Strengths for the Award

Dr. C. Naresh Babu demonstrates numerous qualities and accomplishments that make him a highly suitable candidate for the Best Researcher Award. Some of his key strengths include:

  1. Extensive Academic and Research Experience:
    • Dr. Babu holds a M. Pharm degree and is pursuing advanced research with a Ph.D., showcasing his strong academic background and deep understanding of pharmaceutical sciences.
    • His role as a Junior Research Fellow in a DST-SERB-funded project underscores his involvement in cutting-edge research.
    • As an Assistant Professor at Raghavendra Institute of Pharmaceutical Education & Research (RIPER), he has made significant contributions to the academic development of future professionals in pharmaceutical sciences, teaching a wide array of subjects.
  2. Research Publications and Contributions:
    • Dr. Babu has an impressive publication record, with multiple research articles published in reputed journals such as Future Journal of Pharmaceutical Sciences, Brazilian Journal of Pharmaceutical Sciences, and Indian Journal of Heterocyclic Chemistry, among others.
    • His research has notably focused on drug discovery, tuberculosis, and antimicrobial agents, which are highly relevant areas in current global health concerns.
    • He has contributed to novel compounds and drug discovery, including research on multidrug-resistant tuberculosis and antitubercular agents, which have high potential for impact in the pharmaceutical industry.
  3. Innovative Research Projects:
    • Dr. Babu’s work on 4-oxoazetidin derivatives and their potential to treat multidrug-resistant tuberculosis is groundbreaking, demonstrating his ability to address pressing health issues with innovative solutions.
    • He is involved in in-silico drug design, molecular docking, QSAR studies, and predicting drug toxicity—advanced methodologies that enhance the efficiency and efficacy of drug discovery.
  4. Collaboration and Networking:
    • His collaborative work with other professionals and academic institutions reflects his ability to work as part of a team and engage in multidisciplinary research.
    • His memberships in prestigious organizations such as the Indian Pharmaceutical Association (IPA) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) further illustrate his strong professional network.
  5. Awards and Recognitions:
    • Dr. Babu has received the Best Young Teacher Award from the IPA in 2016, highlighting his dedication to both teaching and research.
    • His consistent academic excellence is demonstrated by his 1st rank in the B. Pharm academic exams in 2006-2008, and his successful qualification in GPAT 2010.

Areas for Improvement 

While Dr. Babu’s profile is very impressive, some areas for further development could include:

  1. Broader International Collaboration:
    • While Dr. Babu’s work is highly valued within national and regional contexts, increasing international research collaborations could further elevate his global research impact.
    • Engaging in international research conferences or working on multi-country research initiatives could enhance visibility and bring exposure to new ideas, techniques, and methodologies.
  2. Research Funding and Leadership:
    • Although he has successfully worked as a Junior Research Fellow in a government-funded project, seeking opportunities to lead or initiate larger-scale projects with funding from international bodies could further strengthen his research profile.
    • Developing leadership roles in collaborative projects could allow Dr. Babu to have a more prominent influence in the global pharmaceutical research community.
  3. Translational Research:
    • Dr. Babu’s research is predominantly focused on drug discovery at a basic research level, which is crucial. However, translating these findings into clinical trials or industry applications could greatly enhance the practical impact of his work. Collaboration with industry partners or clinical researchers could facilitate this transition.
  4. Diversity in Research Topics:
    • While his work on tuberculosis and antimicrobial resistance is vital, expanding into other disease areas or therapeutic approaches (such as cancer, cardiovascular diseases, or neurodegenerative disorders) could increase the scope and impact of his research.

Education

Dr. Naresh Babu completed his Master of Pharmacy (M.Ph) from Sri Padmavathi School of Pharmacy, Tiruchanoor, under JNT University, Anantapur with an impressive 80.37%. He holds a Bachelor of Pharmacy (B.Ph) from A.K. College of Pharmacy, KrishnanKoil, and a Diploma in Pharmacy (D.Ph) from S.V. Govt. Polytechnic, Tirupati. His academic journey also includes Intermediate and Secondary School Certificate from Sri Vidya Darsini Junior College and Mittamalleswara High School, respectively. He further enhanced his research capabilities with a Ph.D. in Pharmaceutical Sciences, focusing on drug development and molecular pharmacology.

Experience

Dr. Naresh Babu has over 12 years of experience in pharmaceutical education and research. He currently serves as an Assistant Professor at RIPER, where he teaches subjects such as Medicinal Chemistry, Pharmaceutical Analysis, and Quality Assurance. Previously, he was a Junior Research Fellow in the DST-SERB funded project, where he focused on drug discovery and testing. Additionally, he has worked as a faculty member at RIPER since 2012, contributing to the academic growth of pharmacy students. Dr. Naresh also has hands-on experience as a pharmacist and intern, having worked in various pharmaceutical settings, including Med Plus Pharmacy and a government hospital in Pulivendla.

Awards and Honors

  • Best Young Teacher Award (2016), recognized by the Executive Council of IPA, Ananthapuramu.
  • Qualified GPAT (2010) with All India Rank 1933.
  • Gold Medal for securing 1st Rank in academic exams in B.Pharm (2006-2008).
  • Recognized for outstanding contributions to research and education, including leadership roles such as Coordinator of Research & Development (R&D) Cell and IQAC at RIPER.
  • Life Member of multiple professional organizations including the Indian Pharmaceutical Association (IPA) and International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Research Focus

Dr. Naresh Babu’s research primarily focuses on drug discovery and the development of novel therapeutic agents. He specializes in synthesizing organic molecules, biological evaluation, and computational methods like QSAR and docking studies. His work addresses the growing challenge of drug-resistant tuberculosis by designing compounds targeting Mycobacterium tuberculosis. Additionally, Dr. Naresh is involved in antimicrobial and anticancer drug development, along with studies on the pharmacokinetic properties of new drug candidates. His multidisciplinary approach integrates synthetic chemistry, biochemistry, and pharmacology to identify innovative solutions for current medical needs.

Publications

  1. Antitubercular Drugs and 4-Oxoazetidin derivatives combination for the treatment of Multidrug-Resistant Tuberculosis 🦠💊
  2. In vitro Antitubercular and Antibacterial activities of isolated constituents and column fractions from Cassia occidentalis, Camellia sinensis, and Ananas comosus 🌿🔬
  3. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance 📚🔍
  4. SYNTHESIS, CHARACTERISATION AND ANTI-TUBERCULAR ACTIVITY OF SOME NEW 3,5-DISUBSTITUTED-2,4-THIAZOLIDINEDIONES 🧪🔥
  5. Spatial Long-Term Memory Retention by Banana and Papaya Peel Extract: In silico and in vivo Evaluation 🍌🍍🧠
  6. Method Development and Validation of Dual Wavelength UV Spectrophotometric Method for Paracetamol and Caffeine 📑💡
  7. Preclinical evaluation of nephroprotective potential of a probiotic formulation LOBUN on Cyclosporine-A induced renal dysfunction 🧬💊
  8. Apoptosis-Mediated Cytotoxic Effect of Caralluma adscendens var. attenuata on Colon and Hepatic Cancer Cell Lines 🍃⚖️
  9. Myoinositol and methyl stearate increases rifampicin susceptibility among drug‐resistant Mycobacterium tuberculosis 🧪💥
  10. Novel stilbene scaffolds efficiently target Mycobacterium tuberculosis nucleoid-associated protein, HU 🦠🔬

Conclusion

Dr. C. Naresh Babu is highly deserving of the Best Researcher Award due to his innovative research contributions, dedication to teaching, and impressive publication record. His work in pharmaceutical sciences, especially in areas related to drug discovery for tuberculosis and antimicrobial resistance, is not only academically significant but also of immense practical importance. By continuing to expand his international collaborations and taking on leadership roles in larger research projects, Dr. Babu could further enhance his global recognition. His ongoing commitment to high-quality research and development makes him a valuable asset to the academic and scientific communities.